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Fatigue level changes with time in long-
term Hodgkin and non-Hodgkin lymphoma
survivors: a joint EORTC-LYSA cross-
sectional study
Raphaël Busson1,2, Marleen van der Kaaij3, Nicolas Mounier4, Berthe M. P. Aleman5, Catherine Thiéblemont6,
Aspasia Stamatoullas7, Vincent Ribrag8, Hervé Tilly7, Corinne Haioun9, René-Olivier Casasnovas10,
Hanneke C. Kluin-Nelemans11 and Michel Henry-Amar2*
Abstract
Background: Long-term lymphoma survivors often complain of persistent fatigue that remains unexplained. While
largely reported in Hodgkin lymphoma (HL), long-term fatigue is poorly documented in non-Hodgkin lymphomas (NHL).
Data collected in two cohort studies were used to illustrate the fatigue level changes with time in the two populations.
Methods: Two cross-sectional studies were conducted in 2009–2010 (HL) and in 2015 (NHL) in survivors enrolled in
European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group and Lymphoma Study
Association (LYSA) trials. The same protocol and questionnaires were used in both studies including the
Multidimensional Fatigue Inventory (MFI) tool to assess fatigue and a checklist of health disorders. Multivariate linear
regression models were used in the two populations separately to assess the influence of time since diagnosis and
primary treatment, age, gender, education level, cohabitation status, obesity and health disorders on fatigue level
changes. Fatigue level changes were compared to general population data.
Results: Overall, data of 2023 HL and 1619 NHL survivors with fatigue assessment available (99 and 97% of cases,
respectively) were analyzed. Crude levels of fatigue were similar in the two populations. Individuals who reported health
disorders (61% of HL and 64% of NHL) displayed higher levels of fatigue than those who did not (P < 0.001). HL survivors
showed increasing fatigue level with age while in NHL survivors mean fatigue level remained constant until age 70 and
increased beyond. HL survivors showed fatigue changes with age higher than those of the general population with
health disorders while NHL survivors were in between those of the general population with and without health disorders.
Conclusions: Among lymphoma survivors progressive increase of fatigue level with time since treatment
completion is a distinctive feature of HL. Our data suggest that changes in fatigue level are unlikely to only
depend on treatment complications and health disorders. Investigations should be undertaken to identify
which factors including biologic mechanisms could explain why a substantial proportion of survivors develop
high level of fatigue.
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Background
Among disease-related symptoms cancer patients generally
complain of, fatigue is probably the most frequently reported
[1]. Common during treatment, fatigue usually decreases
with time to normal levels within few months or years after
successful treatment [2, 3]. In up to one-third of patients fa-
tigue can persist 10 years or more but studies reporting on
fatigue in long-term cancer survivors are limited [4, 5]. Most
of these studies concerned individuals who survived Hodg-
kin lymphoma (HL), few non-Hodgkin lymphomas (NHL)
or both ([2, 3, 6–13], reviews in [14, 15]).
Survival improvement in HL brought physicians’ atten-
tion to persistent fatigue that was observed in a substantial
proportion of survivors, including those who survived
childhood HL, which might exceed 65% [2, 16]. In two
series of lymphoma survivors enrolled in the European
Organisation for Research and Treatment of Cancer
(EORTC) Lymphoma Group and the Lymphoma Study
Association (LYSA) clinical trials, the proportions of indi-
viduals who reported long-term fatigue were 64 and 62%
in HL and NHL survivors, respectively [2, 17]. Factors
generally associated with increased prevalence of fatigue
or increased fatigue level were age, female gender, low
education level, and presence of health disorders. In con-
trast, persistent fatigue was unrelated to primary treat-
ment intensity and treatment given at relapse [14].
Fatigue assessment often varies between studies (longi-
tudinal or cross-sectional) both in time since treatment
end and questionnaires used. Validated specific ques-
tionnaires mostly used were: the Fatigue Questionnaire
(FQ) [18] used in 15 HL and three NHL studies; the
Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT-F) [19] used in four HL studies; the
Multidimensional Fatigue Inventory (MFI) [20] used in
five HL and one NHL studies; and the Fatigue Assess-
ment Scale (FAS) [21] used in three HL studies. Among
validated general questionnaires that include symptoms
items on fatigue, the most often used was the EORTC
Quality-of-Life Core Questionnaire (QLQ-C30) [22]
mentioned in 15 HL and two NHL studies.
The heterogeneity of fatigue assessment tools used, the
patients’ characteristics collected including health disor-
ders and the study designs preclude any reliable compari-
sons and conclusions on whether prevalence of persistent
fatigue differs within survivors of lymphomas or between
cancer survivors. We had the opportunity to analyze fa-
tigue level changes in two cohorts of long-term survivors
of HL and NHL based on the same study design and in-
struments with focus on the effect of age and follow-up.
Patients and methods
Study design
In 2009–2010 the EORTC Lymphoma Group and the
LYSA have designed a cross-sectional study to collect
information on socio-demographic characteristics, health
situation and fatigue of HL survivors enrolled in the
nine clinical trials that were conducted from 1964 to
2004. Two self-administered questionnaires were used in
addition to clinical data prospectively collected and
stored in a unique secured database at the EORTC Head
Quarter in Brussels, Belgium. In 2015 the LYSA repeated
the cross-sectional study in NHL survivors enrolled in
the 12 clinical studies that were conducted from 1993 to
2010. The same two self-administered questionnaires
were used in addition to clinical data prospectively col-
lected and stored in a unique secured database at the
LYSA Academic Research Organisation, Centre Hospita-
lier Lyon-Sud, Pierre-Bénite, France. Survivors were eli-
gible if they had no active lymphoma, had follow-up of 5
years or more, and were free from any cancer treatments
since 4 years. Detailed descriptions of the cross-sectional
studies were previously published [23, 24].
Ethics approval and consent to participate
Authorizations were obtained from the EORTC Scien-
tific and Ethical Committees, the ethical committee and
legal authorities in France, and local ethical committees
at each participating hospital in other European coun-
tries. The study was performed in accordance with the
Declaration of Helsinki.
Survivors voluntarily participated in the survey and
signed informed consent.
Questionnaires and data collection
The Life Situation Questionnaire (LSQ) addresses issues
not available in other validated questionnaires including:
socio-demographic data, cohabitation status and highest
level of education [25]; parenthood data; education, work,
and insurance; health situation including height, weight,
and detailed information (checklist) on post-treatment
health disorders and current treatments; and social situ-
ation [23]. Self-reported health disorders that had occurred
after the end of the lymphoma treatment were grouped as
follows: cardiovascular, pulmonary, and musculoskeletal
disorders; severe infections; anxiety; depression; and history
of second cancer. No attempt was a posteriori made to con-
firm these diseases using data available in either medical re-
cords or computerized clinical data.
The MFI questionnaire was used to address the topic
of fatigue [20]. It consisted of 20 items, each item coded
1 to 5. From the 20 items, five scales were generated:
general fatigue, physical fatigue, reduced activity, re-
duced motivation, and mental fatigue. Each scale was
constructed by summation of its four items; the total ob-
tained was transformed to a linear score ranging from 0
to 100. Zero indicated absence of fatigue and the higher
the score, the higher the level of fatigue.
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Baseline patient characteristics and treatments ad-
ministered were retrieved from the clinical databases.
Age at survey was obtained by subtracting the date of
birth to the date the questionnaires were completed.
Follow-up time was obtained by subtracting the date
of randomization or the date of first treatment to the
date the questionnaires were completed. The weight
(kg)-to-height (m2) ratio was used to calculate the
body mass index (BMI) at the time of survivorship
assessment; obesity was defined as a BMI ≥ 30 kg/m2.
Population study
Overall, 6665 and 8113 patients were enrolled in the
HL and NHL clinical studies, respectively. Of these,
5374 HL (80.6%) and 5051 NHL (62.3%) patients
were alive at the time the surveys started. A postal
address was obtained for 4038 HL and 3317 NHL in-
dividuals. Of these half participated in the survey giv-
ing 2032 HL (50.3%) and 1671 NHL (50.4%) cases
available for analysis (Fig. 1).
Statistical analysis
Clinical characteristics, treatment protocols, and clinical
outcome of NHL survivors have been recently published
[17]; those of HL survivors are under submission for
publication in another journal. Demographic characteris-
tics, follow-up time since treatment initiation and med-
ical history as reported by survivors were described
using numbers and proportions for HL and NHL separ-
ately. Because incidence and initial clinical characteris-
tics and treatment protocols differ between HL and
NHL patients, no comparisons were made between the
two populations. Fatigue scores at the time of survivor-
ship assessment were first expressed using crude mean
and standard deviation for the five dimensions of the
MFI assessment tool for HL and NHL separately. Ad-
justed mean fatigue scores were also estimated using lin-
ear regression models with gender and education level,
age, cohabitation status and obesity at time of survivor-
ship assessment as covariates. The impact of self-
reported health disorders on fatigue level was analyzed
within each lymphoma population using adjusted t-test.
Fig. 1 Study profile and enrollment
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Statistical tests were two-sided with statistical signifi-
cance defined as a P < 0.05.
Analysis of fatigue level changes in long-term survivors
of HL and NHL was performed on cases with fatigue as-
sessment (at least one dimension score) available. Multi-
variate linear regression models were used to assess the
influence of age and time since diagnosis and treatment as
covariates on changes of the five fatigue level scores, i.e.
general fatigue, physical fatigue, mental fatigue, reduced
activity, and reduced motivation. Variables included in the
models were age at the time of survivorship assessment,
follow-up time, gender, education level, cohabitation sta-
tus, obesity and presence of health disorders at fatigue as-
sessment. Primary treatments (including autologous stem-
cell transplantation administered upfront in NHL pa-
tients) were not included in the models because they did
not influence long-term fatigue levels as previously shown
[2, 3, 14, 17]. Salvage treatments delivered for a relapse
were not considered as well for the same reason. In the re-
sults, the intercept (reference score) is the estimation of
the mean fatigue score for a male aged 20 years, living
with partner, with follow-up time equals zero. For age and
follow-up time since treatment initiation the regression
coefficient β estimates the change in score associated with
a 10-year increase. Cases aged ≥70 years (10% of the popu-
lation) were grouped because in a previous study focusing
on NHL it was shown that fatigue level remained un-
changed until 69 years of age and significantly increased
beyond [17]. A score can be estimated by simply adding
the following terms: intercept + (βage < 70 x (age-20)/10)
+ βage ≥ 70 + (βfollow-up x follow-up time/10) + βiVi (where
Vi represents any covariate included in the model and βi
its regression coefficient). Predicted fatigue scores were
plotted according to age assuming that cases had been
treated at age 45 years. No data being available in lymph-
oma survivors on minimal (clinical) important difference
of fatigue changes based on the MFI, the regression coeffi-
cient β estimates were used to test for slopes different
from zero.
An attempt was made to compare fatigue level changes
with time to general population data in which fatigue level
was assessed by use of the MFI instrument [26]. Data con-
sisted of a sample of 1082 individuals (50.3% women; age
range, 20 to 79) with equal size aged strata for whom
socio-demographic determinants were available such as:
education level, cohabitation status, and presence of self-
reported health disorders (i.e. somatic or psychological
disorders including cancer). Estimations of fatigue levels
by age were made with adjustment on gender, education
level and cohabitation status. Fatigue levels by age were
plotted for individuals without and with health disorders
separately. No statistical comparisons were made.
Data were analyzed at the Centre de Traitement des
Données du Cancéropôle Nord-Ouest, Plateforme de
Recherche Clinique Ligue Contre le Cancer, Centre Fran-
çois Baclesse (Caen, France). All analyses were per-
formed with STATA software (version 14.2; STATA
Corp, College Station, Texas 77,845 USA).
Results
Of the 2032 HL survivors and the 1671 NHL survivors
who returned the LSQ and the fatigue assessment ques-
tionnaires, 2023 (99%) HL cases and 1619 (98%) NHL
cases had fatigue assessment available and were included
in the present analysis (Fig. 1). Among HL cases, 197 cases
had radiation therapy alone, 345 were given chemotherapy
alone, and 1447 received combined therapy as part of their
primary treatment; the treatment was not specified in 34
cases. Among NHL cases (1135 with diffuse large B-cell
lymphoma, 461 with follicular lymphoma, and 23 with T-
cell lymphoma), primary treatment consisted of conven-
tional chemotherapy in 780 cases, intensive chemotherapy
(mainly high-dose cyclophosphamide, doxorubicin,
vincristine, prednisone [CHOP] or CHOP-like such as
adriamycin, cyclophosphamide, vindesine, bleomycin,
prednisone [ACVBP]) alone in 505, or combined with au-
tologous stem cell transplantation in 334 [17]. Rituximab
was administered to 807 cases.
HL and NHL characteristics
As expected, NHL cases were 15 years older than HL
cases in average (Table 1). The age also explained the ex-
cess of low educated (elementary school) cases and the
higher proportion of cases living without partner in
NHL population. The number of health disorders re-
ported by the participants at the time of survivorship as-
sessment were similarly distributed in HL and NHL
cases, i.e. 61.5 and 64.4%, respectively; those reporting
three or more health disorders were 26.0 and 26.9%.
However, NHL cases reported twice as many history of
second cancer than HL cases. At the time of survivor-
ship assessment HL and NHL cases expressed similar
crude levels of fatigue than NHL cases in all dimensions.
Levels of fatigue adjusted on gender, age, education level,
cohabitation status and obesity were influenced by the
presence of health disorders at the time the survivorship
assessment was made. HL and NHL survivors reporting
health disorders (any types) had significantly higher
levels of fatigue than those who did not report health
disorders (P < 0.001) (Table 2).
Fatigue level changes with age and follow-up time
The effects of age and time since treatment (adjusted on
gender, age, education level, cohabitation status, obesity
and the presence of health disorders) on the five dimen-
sions of fatigue are shown in Table 3. In HL, mean fa-
tigue levels significantly increased from age 20 to 69 for
all dimensions except mental fatigue. In individuals aged
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N (%) N (%)
Age
Mean (sd) 47.8 (12.3) 62.9 (12.7)
Median (min - max) 46.8 (24–85) 63.9 (24–92)
20–39 years 608 (30.1) 82 (5.1)
40–49 years 573 (28.3) 189 (11.7)
50–49 years 482 (23.8) 345 (21.3)
60–69 years 268 (13.3) 548 (33.8)
70–79 years 77 (3.8) 310 (19.1)
≥ 80 years 15 (0.7) 145 (9.0)
Gender
Male 994 (49.1) 882 (54.5)
Female 1029 (50.9) 737 (45.5)
Education level
University 736 (37.2) 516 (33.6)
High school 646 (32.6) 480 (31.2)
College 479 (24.2) 282 (18.3)
Elementary school 119 (6.0) 260 (16.9)
Unspecified 43 81
Years since treatment start, mean (sd) 15.7 (7.6) 12.8 (4.5)
5 to 9 years 423 (20.9) 511 (31.6)
10 to 14 years 665 (32.9) 561 (34.6)
15 to 19 years 469 (23.2) 362 (21.4)
≥ 20 years 466 (23.0) 185 (11.4)
Cohabitation status
Living without partner
Yes 398 (19.7) 436 (26.9)
No 1625 (80.3) 1183 (73.1)
Body Mass Index (BMI)
BMI ≥ 30 kg/m2 231 (11.4) 264 (16.3)
BMI < 30 kg/m2 1792 (88.6) 1355 (83.7)
Self-reported health disorders
Cardiovascular disorders a
Yes 442 (21.9) 327 (20.2)
No 1581 (78.1) 1292 (79.8)
Pulmonary disorders a
Yes 164 (8.1) 108 (6.7)
No 1859 (91.9) 1511 (93.3)
Severe infections a
Yes 288 (14.2) 200 (12.4)
No 1735 (85.8) 1419 (87.6)
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70 or older, age increased the mean fatigue levels for
physical fatigue, reduced activity and reduced motivation
only. Similarly, mean fatigue levels increased with
follow-up time: a marked influence was noticed for
physical fatigue; it was less important for general fatigue,
reduced activity and reduced motivation. In NHL, an in-
crease in mean fatigue levels with increased age from 20
to 69 years was observed for reduced activity. In con-
trast, physical fatigue level decreased with increasing age
until 69 years. In older cases, the effect of age was of the
same magnitude in all dimensions except mental fatigue.
However, in contrast to HL, follow-up time did not in-
fluence fatigue. The combined influence of age and
follow-up time on mean fatigue scores are illustrated in
Fig. 2. The figures show the predicted mean fatigue
scores 5 years and beyond the start of primary treatment
for non-obese highly educated male survivors treated at
45 years of age, and living with partner. Main differences
between HL and NHL are seen before 70 years of age
with fatigue increasing in HL (Fig. 2a) and being stable
or decreasing in NHL (Fig. 2b). For example, the nega-
tive effect of increasing age (β = − 1.2, Table 3) on gen-
eral fatigue was more pronounced by follow-up time
(β = − 1.3) ending at a slight decrease of fatigue score
with increasing age in NHL. Beyond 70 years of age, the
curves paralleled whatever the fatigue dimension. The
same analyses were repeated on the subgroup of survi-
vors who never relapsed of their disease, and who had a
HL, a diffuse large B-cell lymphoma, or a follicular
lymphoma. Of the 3642 cases, 514 (14.1%) were





N (%) N (%)
Musculoskeletal disorders a
Yes 172 (8.5) 142 (8.8)
No 1851 (91.5) 1477 (91.2)
Anxiety
Yes 184 (9.1) 216 (13.3)
No 1839 (90.9) 1403 (86.7)
Depression or suicide attempt
Yes 251 (12.4) 153 (9.5)
No 1772 (87.6) 1466 (90.5)
Number of self-reported health disorders excluding second cancers
0 780 (38.5) 577 (35.6)
1 423 (20.9) 382 (23.6)
2 295 (14.6) 225 (13.9)
3 202 (10.0) 162 (10.0)
≥ 4 323 (16.0) 273 (16.9)
History of second cancer
Yes 61 (3.0) 127 (7.8)
No 1962 (97.0) 1492 (92.2)
Fatigue assessment
MFI scores, crude mean (sd b)
General fatigue (2020/1605) c 44.8 (29.4) 42.5 (26.4)
Physical fatigue (2018/1577) 38.6 (29.8) 36.7 (27.3)
Reduced activity (2017/1587) 31.8 (26.4) 33.4 (23.9)
Reduced motivation (2018/1585) 26.9 (24.4) 27.2 (23.4)
Mental fatigue (2007/1586) 31.4 (27.4) 28.3 (25.2)
aCardiovascular disorders: heart valve problem, heart rhythm disorder, heart failure, peripheral artery disease, stroke, thrombosis
Pulmonary disorders: pleurisy, lung function deterioration, chronic obstructive pulmonary disease
Severe infections: zona infection, herpes zoster, hepatitis B, hepatitis C, tuberculosis
Musculoskeletal disorders: avascular necrosis of bone, muscular fibrosis, severe osteoarthritis
bsd indicates standard deviation
cNumber of Hodgkin and non-Hodgkin lymphoma survivors with fatigue assessment available
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excluded either because they experienced a relapse (205
HL and 290 NHL), or were of T-cells histological type
(n = 19). Overall, results remained unchanged.
General population comparisons
Predicted mean fatigue scores by age were higher for
both HL and NHL survivors compared with general
population data [26]. Illustrations are given for low edu-
cated males living without partner for whom those who
survived HL had higher fatigue levels in all dimensions
than individuals who survived NHL (Fig. 3a to e). For all
scale scores, HL survivors (61.5% with health disorders)
displayed changes with age higher than those of the gen-
eral population with health disorders; in contrast plots
for NHL survivors (64.4% with health disorders) were in
between those of the general population with and with-
out health disorders except for mental fatigue (Fig. 3e).
Discussion
In the present paper, we report on fatigue changes with
time in long-term survivors of lymphomas, an issue gen-
erally poorly documented concerning its quantitative as-
pect and particularly its relationships with health
disorders. While persistent fatigue in HL survivors has
brought interest of researchers since 1996 [27], the first
publication focusing on NHL survivors was published in
2015 [7]. Above all, when comparisons are made be-
tween series of a given cancer localization or between
cancer localizations, methodologies and instruments for
fatigue assessment used often differ. In recent studies fo-
cusing on lymphomas, data from HL and NHL survivors
were pooled when reporting on long-term fatigue [9–
12]. We had the opportunity to develop two cross-
sectional surveys with the aim to evaluate rehabilitation,
health status, and long-term fatigue in survivors of
lymphomas who participated in clinical protocols con-
ducted by two European cooperative groups. In the two
surveys, the same methodology and the same self-
administered questionnaires were used [23, 24].
With only lymphoma survivors involved in the survey,
our study shows that HL and NHL survivors display
similar long-term fatigue levels in the five dimensions of
the MFI assessment tool. Having or not health disorders
does not change the conclusion. Changes of fatigue level
can be modelled according to time since lymphoma
treatment. Until age 69 years, except for mental fatigue,
fatigue levels progressively increase with time in HL sur-
vivors. In NHL survivors, fatigue levels stay almost un-
changed in all dimensions but two: for reduced activity a
slow increase is observed; for physical activity a slow de-
crease is observed. Beyond 70 years of age, fatigue levels
show parallel increases in both HL and NHL survivors,
with HL figures always above that of NHL in all dimen-
sions except mental fatigue.
In a cross-sectional study conducted in the general
population the MFI questionnaire was used to assess the
level of fatigue and a checklist was proposed to report
health disorders supplemented by an open question
about any other diseases [26]. In this sample, 39.7% of
cases reported health disorders. Mean fatigue levels were
higher (7 to 21 point difference depending of scale
scores) in individuals with health disorders compared
with those without health disorders. Overall, HL and
NHL survivors have fatigue levels of the same magnitude
than what is observed in general population cases with
health disorders. HL survivors with or without self-
Table 2 Adjusted mean MFI scale scores by presence of health disorders at survivorship assessment
Lymphoma
type
Somatic or psychological diseases Adjusted P-value
Absence Presence
No Adjusted mean a (95% CL) b No Adjusted mean (95% CL)
MFI scores
General fatigue HL 780 35.6 (33.7;37.6) 1240 50.5 (49.0;52.1) < 0.001
NHL 573 32.5 (30.4;34.5) 1032 48.0 (46.5;49.5) < 0.001
Physical fatigue HL 777 29.1 (27.2;31.1) 1241 44.6 (43.0;46.1) < 0.001
NHL 567 26.8 (24.6;28.9) 1010 42.3 (40.7;43.9) < 0.001
Reduced activity HL 779 25.9 (24.2;27.7) 1238 35.4 (34.0;36.8) < 0.001
NHL 573 27.7 (25.9;29.6) 1014 36.6 (35.2;38.0) < 0.001
Reduced motivation HL 779 22.8 (21.1;24.4) 1239 29.4 (28.1;30.7) < 0.001
NHL 571 21.9 (20.1;23.7) 1014 30.3 (28.9;31.6) < 0.001
Mental fatigue HL 774 24.9 (23.0;26.8) 1233 35.4 (33.9;36.9) < 0.001
NHL 570 21.7 (19.7;23.7) 1016 31.9 (30.4;33.4) < 0.001
HL Hodgkin lymphoma, NHL non-Hodgkin lymphomas
aAdjustment using linear regression model with gender and education level, and age, cohabitation status and obesity at fatigue assessment as covariates
b95% CL indicates 95% confidence limits of adjusted mean score estimation
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Table 3 Multiple linear regression models on long-term fatigue using MFI assessment
Hodgkin lymphoma Non-Hodgkin lymphomas
Coef β (sd) P-value Coef β (sd) P-value
General fatigue Reference score (intercept) 23.7 (1.9) < 0.001 32.0 (2.9) < 0.001
Age at time of fatigue assessment
per 10-yr increase 20–69 yrs 1.3 (0.6) 0.047 −1.2 (0.7) 0.089
≥ 70 yrs 5.0 (5.1) 0.328 9.5 (1.7) < 0.001
Years since treatment start
per 10-yr increase 1.9 (0.8) 0.018 −1.3 (1.0) 0.194
Gender Male 0.0 0.0
Female 7.1 (1.2) < 0.001 5.2 (1.3) < 0.001
Education level a High 0.0 0.0
Low 3.5 (1.4) 0.015 1.6 (1.4) 0.240
Cohabitation status
living with partner Yes 0.0 0.0
No 4.7 (1.6) 0.003 1.4 (1.4) 0.322
Obesity b No 0.0 0.0
Yes 7.6 (2.0) < 0.001 5.8 (1.7) 0.001
Health disorders No 0.0 0.0
Yes 14.6 (1.3) < 0.001 15.6 (1.3) < 0.001
Physical Fatigue Reference score (intercept) 13.3 (1.9) < 0.001 27.4 (3.0) < 0.001
Age at time of fatigue assessment
per 10-yr increase 20–69 yrs 2.3 (0.6) 0.001 −1.6 (0.7) 0.033
≥ 70 yrs 10.1 (5.0) 0.045 12.2 (1.7) < 0.001
Years since treatment start
per 10-yr increase 3.7 (0.8) < 0.001 −1.0 (1.0) 0.328
Gender Male 0.0 0.0
Female 5.2 (1.2) < 0.001 2.8 (1.3) 0.034
Education level a High 0.0 0.0
Low 3.5 (1.4) 0.012 2.6 (1.4) 0.074
Cohabitation status
living with partner Yes 0.0 0.0
No 4.8 (1.6) 0.002 2.2 (1.5) 0.150
Obesity b No 0.0 0.0
Yes 10.3 (1.9) < 0.001 6.9 (1.8) < 0.001
Health disorders No 0.0 0.0
Yes 14.7 (1.3) < 0.001 15.6 (3.0) < 0.001
Reduced activity Reference score (intercept) 11.4 (1.7) < 0.001 17.3 (2.6) < 0.001
Age at time of fatigue assessment
per 10-yr increase 20–69 yrs 3.4 (0.6) < 0.001 1.6 (0.6) 0.011
≥ 70 yrs 12.8 (4.6) 0.005 11.3 (1.5) < 0.001
Years since treatment start
per 10-yr increase 1.6 (0.7) 0.025 −1.0 (0.9) 0.273
Gender Male 0.0 0.0
Female −0.4 (1.1) 0.723 −0.6 (1.2) 0.611
Education level a High 0.0 0.0
Low 4.2 (1.3) 0.001 2.2 (1.3) 0.074
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Table 3 Multiple linear regression models on long-term fatigue using MFI assessment (Continued)
Hodgkin lymphoma Non-Hodgkin lymphomas
Coef β (sd) P-value Coef β (sd) P-value
Cohabitation status
living with partner Yes 0.0 0.0
No 7.9 (1.4) < 0.001 3.2 (1.3) 0.015
Obesity b No 0.0 0.0
Yes 5.6 (1.7) 0.001 5.2 (1.5) 0.001
Health disorders No 0.0 0.0
Yes 9.2 (1.2) < 0.001 8.9 (1.2) < 0.001
Reduced motivation Reference score (intercept) 7.4 (1.6) < 0.001 12.6 (2.6) < 0.001
Age at time of fatigue assessment
per 10-yr increase 20–69 yrs 3.7 (0.5) < 0.001 0.8 (0.6) 0.212
≥ 70 yrs 12.7 (4.2) 0.003 10.3 (1.5) < 0.001
Years since treatment start
per 10-yr increase 1.5 (0.7) 0.022 −0.5 (0.9) 0.582
Gender Male 0.0 0.0
Female 0.4 (1.0) 0.692 2.6 (1.1) 0.020
Education level a High 0.0 0.0
Low 4.0 (1.2) 0.001 3.4 (1.2) 0.005
Cohabitation status
living with partner Yes 0.0 0.0
No 6.0 (1.3) < 0.001 4.7 (1.3) < 0.001
Obesity b No 0.0 0.0
Yes 7.1 (1.6) < 0.001 4.0 (1.5) 0.008
Health disorders No 0.0 0.0
Yes 6.5 (1.1) < 0.001 8.4 (1.2) < 0.001
Mental fatigue Reference score (intercept) 19.3 (1.8) < 0.001 21.4 (2.9) 0.002
Age at time of fatigue assessment
per 10-yr increase 20–69 yrs 0.6 (0.6) 0.318 −0.9 (0.7) 0.211
≥ 70 yrs −0.2 (4.9) 0.965 3.4 (1.7) 0.043
Years since treatment start
per 10-yr increase −0.6 (0.8) 0.431 −0.2 (1.0) 0.866
Gender Male 0.0 0.0
Female 3.4 (1.2) 0.005 1.4 (1.3) 0.282
Education level a High 0.0 0.0
Low 4.7 (1.4) 0.001 4.2 (1.4) 0.002
Cohabitation status
living with partner Yes 0.0 0.0
No 4.4 (1.5) 0.003 4.0 (1.4) 0.006
Obesity b No 0.0 0.0
Yes 2.6 (1.9) 0.159 −0.1 (1.7) 0.929
Health disorders No 0.0 0.0
Yes 10.7 (1.3) < 0.001 10.2 (1.3) < 0.001
sd indicates standard deviation
aHigh education level indicates university or high school; low education level indicates college, elementary school or level unspecified
bObesity indicates Body Mass Index (BMI) ≥ 30 kg/m2
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reported health disorders always display higher levels of
fatigue than general population cases with similar socio-
demographic characteristics. In contrast, the figures dif-
fer in NHL survivors. Those with no self-reported health
disorders have higher levels of general fatigue and re-
duced activity than individuals of the general population
with the same characteristics. However, NHL survivors
who report health disorders have levels of fatigue com-
parable to that of the general population with health dis-
orders except for mental fatigue for which the levels are
slightly increased. Using multiple regression analysis on
general population data, age, gender, low education level,
living without partner and presence of health disorders
(mostly depression) significantly increased the level of
fatigue with various impact according to scale scores
[26]. These results were used to illustrate changes in fa-
tigue levels according to age in HL, NHL, and general
population with and without health disorders separately.
The figures confirm that HL survivors suffer from long-
term fatigue of similar magnitude if not higher than in-
dividuals with health disorders in the general population.
Our study confirms that a substantial proportion of
long-term lymphoma survivors develop diseases that can
favor the development or the persistence of fatigue.
Although the numbers of individuals who complain of
health disorders are rather similar among HL and NHL
survivors, their types differ and we have shown that each
of them have similar impact on the levels of fatigue [17,
unpublished data]. Besides diseases, other individual
characteristics can play a role on the development of fa-
tigue such as a low education level, living without part-
ner, and obesity. In contrast, the fatigue level is in
almost all studies independent of treatments (primary
treatment or given at relapse) as previously reported [2,
3, 14, 28]. It is also independent of NHL histological
type-related treatments [7, 29].
It is unlikely that differences observed between HL
and NHL survivors in changes of fatigue levels with age
before 70 years can simply be explained by the presence
of health disorders. Epstein-Barr virus (EBV) infection
has long been described in classical HL and, in European
countries, its prevalence ranges from 31 to 40% [30]. It
is associated with increased cytokine levels [31]; and
genome-level mutations responsible for cytokine pro-
duction induce increased fatigue level in breast cancer
survivors [32, 33]. Recently, a study performed in fa-
tigued patients with solid tumors showed that a high
level of IL-1 and IL-1 Ra cytokines correlates with high
Fig. 2 MFI assessment: Changes of mean fatigue scores in HL (panel a) and NHL (panel b) with age. Predicted mean fatigue scores for high
educated, non-obese male survivors living with partner, treated at 45 years of age. Curves start at age 50 because all survivors had at least 5 years
of follow-up at the time of survivorship assessment. On the X-axis, age minus 45 equals follow-up
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levels of fatigue [34]. Variations in neurotransmitter genes
have also been associated with the development of chronic
fatigue in breast cancer [35]. These results suggest that fa-
tigue could have in part a genetic origin. On the other
hand, a substantial proportion of newly diagnosed patients
with HL display T-lymphocytopenia that can persist long
after the disease is cured suggesting chronic immunologic
impairment that can relate to genetic or environmental
origin [36]. NHL survivors might also suffer from im-
munodeficiency as indirectly suggested by a history of in-
fections prior to diagnosis [37]. However, no genetic
studies focusing on immunodeficiency and fatigue in
lymphoma patients, at diagnosis or long after the treat-
ment was completed, have been conducted so far. HL pa-
tients can also present at diagnosis with lymphocyte
telomeres length shorter than that of healthy individuals
[38]. Since leukocyte telomeres length reduction was
shown to be associated with fatigue level in nondis-
abled older adults [39], one can question whether the
association of multiple genetic mutations pre-existing
the disease could concur to pre-treatment and/or
long-term abnormal fatigue in lymphoma patients.
Conclusions
Persistent fatigue is a symptom commonly reported by
cancer survivors [1] interfering with patients’ (quality of )
life. Often studied in Hodgkin lymphoma, its prevalence
is poorly known in non-Hodgkin lymphomas. We used
self-reported fatigue data from two European cross-
sectional studies conducted in long-term survivors. In
both studies fatigue level was assessed and health
disorders were collected using the same questionnaires.
Overall, 2023 and 1619 individuals with Hodgkin and
non-Hodgkin lymphomas were available allowing com-
parisons of fatigue level changes with time based on
multivariate linear regression modeling. At time of sur-
vivorship assessment, Hodgkin and non-Hodgkin lymph-
oma survivors expressed similar crude mean levels of
fatigue in all MFI dimensions. In both groups, fatigue
levels were linked to the presence of health disorders
(P < 0.001). In Hodgkin lymphoma survivors, fatigue
levels increased linearly with age; in non-Hodgkin
lymphoma survivors, fatigue levels remained constant
until age 70 and increased afterwards parallel to what
was observed in Hodgkin lymphoma. Compared to
Fig. 3 MFI assessment: Changes of mean fatigue scores in HL, NHL, and general population with age: General fatigue (panel a), physical fatigue
(panel b), reduced activity (panel c), reduced motivation (panel d), and mental fatigue (panel e). Predicted mean fatigue scores (solid lines) for
Hodgkin () and non-Hodgkin lymphomas () low educated males survivors, living alone, treated at 45 years of age. Predicted mean fatigue scores
for general population (dash lines) with (▲) and without (▼) health disorders [17]
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general population data, Hodgkin lymphoma survivors
showed fatigue level changes with age parallel and
higher than those of the general population with health
disorders. In contrast, non-Hodgkin lymphoma survivors
displayed fatigue level changes with age in between those
of the general population with and without health
disorders.
Our study is the first reporting on direct comparison
between Hodgkin and non-Hodgkin lymphoma survi-
vors. It also provides indications on fatigue level changes
with time with indirect comparison with general popula-
tion data. No medical explanations exist for why fatigue
develops or persists in some patients. In particular, long-
term fatigue is unrelated to lymphoma treatments [2, 3,
14, 17]. Therefore, time has probably come to investigate
its biologic origin. Conclusive results could then be used
to select patients who would benefit from various ter-
tiary prevention interventions to manage or prevent the
development of persistent fatigue [40–42].
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